Medicis reveals purchase price
This article was originally published in The Gray Sheet
Executive Summary
Thanks to the close of the Allergan/Inamed deal, Medicis' exclusive license of Ipsen's Reloxin botulinum toxin type A product goes through for $90.1 mil. in cash, plus nearly $103 mil. in milestone payments. Ipsen will manufacture the product and Medicis will have the right to develop and distribute the product exclusively until 2019. Inamed previously had rights to the product but divested them in order to avoid antitrust snags due to Allergan's existing Botox product (1"The Gray Sheet" March 20, 2006, p. 17)...
You may also be interested in...
Allergan’s Inamed Purchase Delayed; Reloxin Will Go To Medicis
Allergan was forced to push back its $3.2 bil. purchase of Inamed after failing to obtain the requisite amount of stock from Inamed shareholders
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.